Navigation Links
AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology

----------- * nCR = Near Complete Response is defined as meeting the criteria for CR (non-detectable monoclonal protein by serum and urine), except with detectable monoclonal protein by immunofixation. ** SD = Stable Disease for a minimum of 3 months.

Approximately 60% (45 / 73) of patients demonstrated progression (or SD for 4 cycles) at some point in their treatment and received 20 mg dexamethasone, four times per week, in addition to perifosine plus bortezomib. Responses occurred both with patients taking perifosine in combination with bortezomib and with patients receiving the combination plus dexamethasone. Best response for each group was as follows:

    Best Response        CR/nCR      PR         MR        ORR        SD
    + Bortezomib
    (n=73)    2   3%   10   14%    6    8%   18   25%   19   26%
    Dexamethasone added
    (n=45)    1   2%    6   13%   10   23%   17   38%   14   31%

Five patients achieved an initial response on perifosine + bortezomib alone, and subsequently responded again with the addition of dexamethasone. Three additional patients achieved stable disease on perifosine + bortezomib alone, and subsequently achieved stable disease again with the addition of dexamethasone.

Reported for the first time was median Progression-Free Survival (PFS) and Overall Survival (OS) data for all evaluable patients, as follows:

    Evaluable Patients          Median PFS*         Median OS**
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
(Date:10/9/2015)... ROCKVILLE, Md. , Oct. 9, ... biotechnology company developing next generation vaccines based on ... entered into an exclusive worldwide licensing agreement with ... treatment or prevention of any and all allergic ... Immunomic Therapeutics will receive an upfront payment of ...
(Date:10/9/2015)... CA (PRWEB) , ... October 09, 2015 , ... Leading ... study that aims to better understand the relationship between weight management and the microbiome. ... and more accurately from participants using an iPhone app. , The uBiome app is ...
(Date:10/8/2015)... 2015  Genetic testing for mutations beyond those currently ... more couples at risk of having a child with ... the 2015 American Society of Human Genetics (ASHG) Annual ... Baltimore, Maryland . The study is one of ... ) are presenting at the conference this week demonstrating ...
(Date:10/8/2015)... October 8, 2015 ... --> Goldman Small Cap Research, a ... cap and microcap sectors, announced today that it ... PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly ... and preparing treatments for cancer and diabetes. To ...
Breaking Biology Technology:
... importance on ... indication-specific FDA approval, WALTHAM, Mass., April 2, 2008 ... into the marketing of biliary,stents for off-label uses in the ... could become a key focus for,stent manufacturers. A recent study ...
... 2008 Pharmaceutical,companies currently challenged with replacing the ... patent in the next four years must dramatically,rethink ... a new report,released by Deloitte today., According ... R&D in the Future,Pharmaceutical Landscape ( ), ...
... Amsterdam,Molecular Therapeutics (Euronext: AMT), a leader in ... AMT,s Supervisory Board has decided to,propose Dr. George ... at its,Annual General Meeting of shareholders on April ... retired as Senior Vice President of Development at,Amgen, ...
Cached Biology Technology:
(Date:9/28/2015)... JOSE, Calif. , Sept. 28, 2015 ... of human interface solutions, today announced that Lenovo has ... touch fingerprint sensor, FS4202, for its latest smartphone, the ... secure, password-free access to unlock the device and provide ... The feature-rich Natural ID FS4202 sensor ...
(Date:9/10/2015)... Sept. 10, 2015 This report provides detailed ... products today, and emerging sensor types that will dominate ... the peak of the wearable technology hype curve in ... disillusionment. The common feature with all of them is ... for their most useful functions. Sensors collect data about ...
(Date:9/10/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces that the San ... will feature the Wocket® smart wallet for the first ... Touch Of Modern is an online retailer ... its 7.2 million members. Customers are affluent, urban influencers ...
Breaking Biology News(10 mins):
... 2013) In what is anticipated to be a ... York Stem Cell Foundation (NYSCF) Research Institute is partnering ... Program (UDP). NYSCF scientists will generate stem cell ... with UDP researchers to better understand and potentially treat ...
... Huanglongbing (HLB) or citrus greening is a bacterial ... and poses a serious threat to the citrus industry. ... disrupting the trees, food transportation systems. To address ... rapidly characterize citrus varieties and hybrids and locate genes ...
... frogs and toads on national wildlife refuges. The rate of abnormalities ... overall indicating that the malformations first reported in the mid-1990s ... local "hotspots," suggesting that where these problems occur they have local ... PLOS ONE . "We now know what the baseline is ...
Cached Biology News:
... for 25 chips provides the chips and ... (at picogram levels) with the Experion automated ... HighSens microfluidic chips, 2 x 1,250 microliters ... HighSens stain, 20 microliters RNA ladder, 2 ...
Vitronectin Immunogen: Purified, full length, native human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... StdSens analysis kit for 25 chips provides ... standard-sensitivity RNA analysis (at nanogram levels) with ... includes 25 RNA StdSens microfluidic chips, 2 ... 20 microliters RNA StdSens stain, 2 x ...
... White solid. PROTECT FROM LIGHT. PACKAGED UNDER ... pyrimidinone compound that acts as a potent ... (IC 50 = 200 nM and ... with little activity against the dehydrogenase activity ...
Biology Products: